Schmid John P.

CIK 000147891611 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001478916

Recent Transactions

50 trades

Award
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2026-01-06+5,500→ 5,500 total
Award
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2026-01-06+4,000→ 4,000 total
Exercise/Conversion
BridgeBio Oncology Therapeutics, Inc.$BBOT
Class B ordinary shares
2025-08-11−30,000→ 0 total
Exercise/Conversion
BridgeBio Oncology Therapeutics, Inc.$BBOT
Common Stock
2025-08-11+30,000→ 30,000 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2025-06-15−6,030→ 0 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Common Stock
2025-06-15+6,030→ 52,267 total
Award
Design Therapeutics, Inc.$DSGN
Stock Option (right to buy)
2025-06-10+19,000→ 19,000 total
Other
ANAPTYSBIO, INC$ANAB
Common Stock
2025-03-25$18.18/sh+11,068→ 11,068 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2025-01-13−20,645→ 0 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2025-01-13−21,692→ 0 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Common Stock
2025-01-13$4.55/sh+21,692→ 25,592 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Common Stock
2025-01-13$8.54/sh+20,645→ 46,237 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−27,350→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−16,038→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−25,833→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−20,000→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−32,076→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−27,350→ 0 total
Disposition from Tender
Poseida Therapeutics, Inc.
Common Stock
2025-01-08−58,950→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−20,000→ 0 total
Disposition to Issuer
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2025-01-08−28,500→ 0 total
Award
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2025-01-07+16,510→ 16,510 total
Award
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2025-01-07+6,030→ 6,030 total
Purchase
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2024-08-12$2.25/sh+4,515→ 25,200 total
Purchase
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2024-08-09$2.37/sh+4,285→ 20,685 total
Award
Poseida Therapeutics, Inc.
Common Stock
2024-06-17+19,650→ 58,950 total
Award
Poseida Therapeutics, Inc.
Stock Option (Right to buy)
2024-06-17+27,350→ 27,350 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Common Stock
2024-06-15+3,900→ 3,900 total
Exercise/Conversion
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2024-06-15−3,900→ 0 total
Award
Design Therapeutics, Inc.$DSGN
Stock Option (right to buy)
2024-06-13+19,000→ 19,000 total
Award
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2024-06-05+50,000→ 113,159 total
Purchase
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2024-05-10$1.91/sh+5,400→ 16,400 total
Purchase
Design Therapeutics, Inc.$DSGN
Common Stock
2024-03-25$3.74/sh+17,809→ 26,965 total
Purchase
Design Therapeutics, Inc.$DSGN
Common Stock
2024-03-22$3.62/sh+9,156→ 9,156 total
Purchase
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2024-03-14$2.16/sh+4,500→ 11,000 total
Award
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2024-01-03+16,510→ 16,510 total
Award
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2024-01-03+6,030→ 6,030 total
Purchase
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2023-11-16$1.51/sh+6,500→ 6,500 total
Award
Poseida Therapeutics, Inc.
Stock Option (Right to buy)
2023-06-15+27,350→ 27,350 total
Award
Poseida Therapeutics, Inc.
Common Stock
2023-06-15+19,650→ 39,300 total
Award
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2023-06-07+42,500→ 63,159 total
Award
Design Therapeutics, Inc.$DSGN
Stock Option (right to buy)
2023-05-31+15,000→ 15,000 total
Award
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2023-01-06+10,600→ 10,600 total
Award
ANAPTYSBIO, INC$ANAB
Restricted Stock Unit
2023-01-06+3,900→ 3,900 total
Award
Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
2022-06-16+28,500→ 28,500 total
Award
Poseida Therapeutics, Inc.
Common Stock
2022-06-16+19,650→ 19,650 total
Award
Design Therapeutics, Inc.$DSGN
Stock Option (right to buy)
2022-06-15+15,000→ 15,000 total
Award
Xeris Biopharma Holdings, Inc.$XERS
Stock Option (Right to Buy)
2022-06-08+25,000→ 25,000 total
Award
Xeris Biopharma Holdings, Inc.$XERS
Common Stock
2022-06-08+15,000→ 20,659 total
Award
ANAPTYSBIO, INC$ANAB
Stock Option (right to buy)
2022-02-10+9,200→ 9,200 total

Companies

Recent Filings

Address

C/O CORMORANT ASSET MANAGEMENT LP 200 CLARENDON STREET, 52ND FLOOR

BOSTON, MA, 02116

View on SEC.gov